Ascletis Pharma Inc. (2VJ.F)

0,1500 -0,0020 (-1,32%) Ab 09:59AM CEST. Markt geöffnet.

Ascletis Pharma Inc.

Building D
12th Floor 198 Qidi Road, HIPARK Xiaoshan District
Hangzhou
China
86 571 8538 9730
https://www.ascletis.com

Sektor(en): Healthcare
Branche: Biotechnology
Vollzeitmitarbeiter: 219

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Dr. Jinzi Jason Wu Ph.D.	Founder, Chairman & CEO	2,91M	N/A	1964
Ms. Hejingdao Wu	Senior VP of Operations & Executive Director	344k	N/A	1975
Ms. Yuemei Yan	Senior Vice President of Clinical Development Operations	N/A	N/A	1970
Dr. Kristjan Sigurdur Gudmundsson	Senior Consultant & Head of Discovery	N/A	N/A	1968
Dr. George Zhengzhi Hill	Senior Consultant & Chief Medical Advisor	N/A	N/A	1951
Mr. John P. Gargiulo M.B.A.	Chief Business Officer	N/A	N/A	N/A
Mr. Ming Fai Chung CPA	Company Secretary	N/A	N/A	1980

Die Beträge haben den Stand 31. Dezember 2022 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in EUR.

Beschreibung

Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China and internationally. The company offers Ritonavir oral tablet, a pharmacokinetic booster of various oral antiviral drugs targeting viral proteases and a component of the approved oral antiviral drug Paxlovid; ASCLEVIR and GANOVO for the treatment of Hepatitis C virus. It is also developing ASC22 for treating chronic hepatitis B (CHB); ASC42 for chronic hepatitis B functional cure; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, ASC42, ASC43F FDC, ASC44F FDC, and ASC45F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma, drug resistant breast cancer, and KRAS mutant non-small cell lung cancer; ASC61 and ASC63 for advanced solid tumors; ASC60 to treat solid tumors; and ASC40 for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is headquartered in Hangzhou, the People's Republic of China.

Corporate Governance

Ascletis Pharma Inc.s ISS Governance QualityScore, Stand N/A, lautet N/A. Die grundlegenden Scores sind Audit: N/A, Vorstand: N/A, Shareholderrechte: N/A, Kompensation: N/A.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.